Juliette Mijangos-Sanchez

Juliette Mijangos-Sanchez

Auto-generated profile, based on publicly available information

Juliette Mijangos-Sanchez

Laboratory of Pharmaco-Chemistry, Faculty of Chemical Biological Sciences, University Autonomous of Campeche, Av. Agustín Melgar s/n, Col Buenavista C.P. 24039 Campeche, Camp., México

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Brazilian Journal of Science
Verified
Journal Article
Open access
PDF file
FLFigueroa Lauro
Figueroa Lauro
FDFrancisco Diaz-Cedillo
Francisco Diaz-Cedillo
MNMarcela Rosas Nexticapa
Marcela Rosas Nexticapa
MAMagdalena Alvarez-Ramirez
Magdalena Alvarez-Ramirez
MLMaria López-Ramos
Maria López-Ramos
JMJuliette Mijangos-Sanchez
Juliette Mijangos-Sanchez
Several genetic expressions have been involved in the development of cancer such as the expression of a ribosomal kinase S6 P90 (RSK-4). It is important to mention that some compounds such as LJH685, 2073047-06-8, and SL0101 can act as RSK-4 inhibitors; however, its interaction with the surface of RSK-4 is very confusing. The aim of this research was to evaluate the interaction of twenty-nine steroid derivatives (1 to 29) with of RSK-4 surface using 6rv2 protein, LJH685, 2073047-06-8 and SL0101 as theoretical tools in the Dockingserver program. The results showed differences in the aminoacid residues involved in the interaction of steroid derivatives with 6rv2 protein surface compared with LJH685, 2073047-06-8 and SL0101. Besides, the inhibition constant for steroid derivatives 1, 12, 14, 19 and 22 was lower compared to 2073047-06-8 drug. In conclusion, the steroid derivatives 1, 12, 14, 19 and 22 could be a good alternative as RSK-4 inhibitors to decrease cancer cells growth.